Table 5.
Multivariable Cox regression model for the development of anemia.
| Model 1a | Model 2b | Model 3c | Model 4d | |||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| FGF23 quartile | ||||||||
| Quartile 1 | Reference | Reference | Reference | Reference | ||||
| Quartile 2 | 1.65 (1.13–2.40) | 0.009 | 1.48 (1.02–2.16) | 0.04 | 1.23 (0.81–1.87) | 0.34 | 1.22 (0.80–1.85) | 0.36 |
| Quartile 3 | 2.55 (1.80–3.62) | <0.001 | 2.15 (1.51–3.07) | <0.001 | 1.71 (1.15–2.54) | 0.008 | 1.66 (1.11–2.47) | 0.01 |
| Quartile 4 | 2.94 (2.07–4.17) | <0.001 | 2.42 (1.70–3.45) | <0.001 | 1.95 (1.31–2.90) | 0.001 | 1.84 (1.23–2.76) | 0.003 |
| FGF23 (per 1 log) | 1.32 (1.22–1.43) | <0.001 | 1.26 (1.16–1.36) | <0.001 | 1.19 (1.08–1.31) | <0.001 | 1.17 (1.07–1.29) | 0.001 |
Note: FGF23 entered as a categorical and continuous form (log transformed).
aUnadjusted model.
bAdjusted for age, sex, DM, BMI, SBP, CCI, smoking status.
cAdjusted for Model 2 + eGFR, albumin, phosphorus, 1,25(OH)2 vitamin D, iron deficiency, hepcidin*, CRP*, and proteinuria*.
dAdjusted for Model 3 + iron replacement and ESA therapy.
*Variables were log transformed.
Abbreviations: FGF23, fibroblast growth factor 23; DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; CCI, Charlson comorbidity index; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; ESA, erythropoiesis-stimulating agent.